Moreover, patients with high CAFDL scores had a significantly worse prognosis than those with low CAFDL scores in Braun’s cohort (clear cell renal cell carcinoma treated with anti–PD-1 antibody), Gide’s cohort, IMvigor210 (bladder urothelial carcinoma treated with anti–programmed death ligand 1 (PD-L1) antibody), Liu’s cohort (melanoma treated with anti–PD-1 antibody), and Nathanson’s cohort (melanoma treated with anti–CTLA-4 antibody) (all P < 0.05; Figure 5A). The gene discussed is PDCD1; the disease is bladder transitional cell carcinoma.